伊克齐祖马布改善了与共发性扩散性脱发相关的耐火性皮质质银病:一个病例报告与52周的随访
Biao Song1,2,3, Xiaohan Liu1,2,3, Hongzhong Jin1,2,3
1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Clinical, cosmetic and investigational dermatology
|August 14, 2024
概括
红皮质牛皮 (EP) 与相关的脱发可能是严重的. 一名患有耐治疗PE和脱发的患者通过ixekizumab实现了完全的皮肤和头发再生.
科学领域:
- 皮肤病学 皮肤病学
- 临床医学 临床医学
背景情况:
- 皮质皮质牛皮 (EP) 是一种罕见的,严重的牛皮形式,影响超过90%的身体表面积.
- 相关的脱发可能会显著损害患者的生活质量.
研究的目的:
- 报告严重的红皮性牛皮病与扩散性脱发症的病例.
- 为了评估ixekizumab在对常规疗法的耐药性患者中的疗效.
主要方法:
- 一名患有严重PE和扩散性脱发症的患者,对标准治疗无反应,被给予ixekizumab.
- 使用牛皮面积和严重程度指数 (PASI) 评估皮肤病变,用牛皮严重程度工具 (SALT) 评估脱发的治疗疗效.
主要成果:
- 伊克西祖马布治疗导致牛皮性皮肤病变的完全消失,达到PASI 100.
- 患者还经历了头发的完全再生,脱发达到SALT 0.
- 治疗有效地解决了严重的皮肤表现和相关的脱发.
结论:
- 伊克西祖马布是一种潜在的治疗选择,用于严重的皮质皮质银病与相关的脱发.
- 通过ixekizumab.com实现了皮肤和头发症状的完全消失.
- 这一案例突显了针对性生物治疗在耐火性EP的疗效.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K


